- 全部删除
 
您的购物车当前为空
Lixivaptan (VPA-985) 是一种具有口服活性的选择性加压素受体 V2 拮抗剂,对人和大鼠的IC50值分别为 1.2 和 2.3 nM。


为众多的药物研发团队赋能,
让新药发现更简单!
Lixivaptan (VPA-985) 是一种具有口服活性的选择性加压素受体 V2 拮抗剂,对人和大鼠的IC50值分别为 1.2 和 2.3 nM。
| 规格 | 价格 | 库存 | 数量 | 
|---|---|---|---|
| 1 mg | ¥ 269  | In stock | |
| 2 mg | ¥ 379  | In stock | |
| 5 mg | ¥ 598  | In stock | |
| 10 mg | ¥ 995  | In stock | |
| 25 mg | ¥ 2,290  | In stock | |
| 50 mg | ¥ 3,990  | In stock | |
| 100 mg | ¥ 5,680  | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 666  | In stock | 
LIXIVAPTAN 相关产品
| 产品描述 | Lixivaptan (VPA-985) is an orally active and selective vasopressin receptor V2 antagonist(Ki = 2.3 nM)  | 
| 靶点活性 |  V2 receptor (rat):2.3 nM (IC50), V2 receptor (human):1.2 nM (IC50)  | 
| 体内活性 | 与多囊肾表型的发展一致,对照的PCK大鼠表现出肾脏增大、广泛的囊肿形成以及12周龄时血清肌酐初期升高迹象。与对照组相比,接受低剂量lixivaptan治疗的PCK大鼠显示出以下改善:肾脏重量占体重百分比降低了26%(p < 0.01);肾囊性评分降低了54%(p < 0.001),这是衡量囊肿负担的组织形态学指标;肾脏cAMP水平降低了23%(p < 0.05),这是疾病的生化标志;血浆肌酐降低了13%(p < 0.001),表明肾功能得到保留。这些降低与24小时尿产量增加3倍相关,显示了lixivaptan的强大利尿效应[1]。  | 
| 动物实验 | Four-week old PCK rats were fed rodent chow with 0.5% lixivaptan (low dose) or 1% lixivaptan (high dose), or chow only (control) for 8 weeks.?Urine output was measured at weeks 7 and 10 of age.?Animals were killed at 12 weeks of age;?kidneys and livers were collected, weighted, and analyzed for cyclic adenosine 3',5'-monophosphate (cAMP) levels and cystic burden and fibrosis;?serum creatinine and sodium were measured[1].  | 
| 别名 | 利伐普坦, WAY-VPA 985, VPA-985 | 
| 分子量 | 473.93 | 
| 分子式 | C27H21ClFN3O2 | 
| CAS No. | 168079-32-1 | 
| Smiles | Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1 | 
| 密度 | 1.32 g/cm3 | 
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 150 mg/mL (316.5 mM), Sonication is recommended.   | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.44 mM), Sonication is recommended.  请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表  | ||||||||||||||||||||||||||||||||||||
DMSO 
  | ||||||||||||||||||||||||||||||||||||
评论内容